Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.
作者信息
Sharma Ayush, Oishi Naoki, Boddicker Rebecca L, Hu Guangzhen, Benson Hailey K, Ketterling Rhett P, Greipp Patricia T, Knutson Darlene L, Kloft-Nelson Sara M, He Rong, Eckloff Bruce W, Jen Jin, Nair Asha A, Davila Jaime I, Dasari Surendra, Lazaridis Konstantinos N, Bennani N Nora, Wu Tsung-Teh, Nowakowski Grzegorz S, Murray Joseph A, Feldman Andrew L
机构信息
Division of Gastroenterology and Hepatology and.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
出版信息
Blood. 2018 May 17;131(20):2262-2266. doi: 10.1182/blood-2018-01-830968. Epub 2018 Mar 28.
Abstract
摘要
相似文献
1
Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.胃肠道惰性T细胞淋巴增殖性疾病中的复发性融合
Blood. 2018 May 17;131(20):2262-2266. doi: 10.1182/blood-2018-01-830968. Epub 2018 Mar 28.
2
Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.STAT3-JAK2融合蛋白的靶向性：对胃肠道T细胞淋巴增殖性疾病的影响。
Leukemia. 2020 May;34(5):1467-1471. doi: 10.1038/s41375-019-0678-3. Epub 2019 Dec 13.
3
Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.胃肠道惰性 T 细胞淋巴组织增生性疾病。
Blood. 2013 Nov 21;122(22):3599-606. doi: 10.1182/blood-2013-07-512830. Epub 2013 Sep 5.
4
Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.胃肠道惰性 T 细胞淋巴增生性疾病的遗传和表型特征。
Haematologica. 2020 Jul;105(7):1895-1906. doi: 10.3324/haematol.2019.230961. Epub 2019 Sep 26.
5
Oral manifestation of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: A potential diagnostic pitfall.胃肠道惰性T细胞淋巴增殖性疾病的口腔表现：一个潜在的诊断陷阱。
J Cutan Pathol. 2020 May;47(5):494-496. doi: 10.1111/cup.13658. Epub 2020 Feb 11.
6
Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.胃肠道淋巴组织增生性疾病的最新进展：从惰性淋巴增生到侵袭性淋巴瘤的疾病谱。
Virchows Arch. 2020 May;476(5):667-681. doi: 10.1007/s00428-019-02704-8. Epub 2019 Nov 26.
7
JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.汉族人群 Behçet 病中 JAK2 和 STAT3 多态性。
Invest Ophthalmol Vis Sci. 2012 Jan 31;53(1):538-41. doi: 10.1167/iovs.11-8440.
8
An unusual case report of indolent T-cell lymphoproliferative disorder with aberrant CD20 expression involving the gastrointestinal tract and bone marrow.一例罕见的惰性T细胞淋巴增殖性疾病伴异常CD20表达累及胃肠道和骨髓的病例报告。
Diagn Pathol. 2018 Oct 20;13(1):82. doi: 10.1186/s13000-018-0762-4.
9
Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update.胃肠道惰性T细胞和NK细胞淋巴增殖性疾病：综述与更新
Hematol Oncol. 2017 Mar;35(1):3-16. doi: 10.1002/hon.2317. Epub 2016 Jun 29.
10
[Expression and Clinical Significance of Peripheral Blood T cell JAK2/STAT3 mRNA in Chronic Idiopathic Thrombocytopenic Purpura].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Dec;26(6):1746-1751. doi: 10.7534/j.issn.1009-2137.2018.06.028.
引用本文的文献
1
Effective venetoclax treatment for indolent T-cell lymphoma of the gastrointestinal tract: a case report and literature review.维奈托克治疗胃肠道惰性T细胞淋巴瘤的有效性：一例报告及文献综述
Front Immunol. 2025 Jul 1;16:1593343. doi: 10.3389/fimmu.2025.1593343. eCollection 2025.
2
Exploring the boundaries between neoplastic and reactive lymphoproliferations: lymphoid neoplasms with indolent behavior and clonal lymphoproliferations-a report of the 2024 EA4HP/SH lymphoma workshop.探索肿瘤性与反应性淋巴细胞增殖之间的界限：具有惰性行为的淋巴肿瘤和克隆性淋巴细胞增殖——2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Jul 5. doi: 10.1007/s00428-025-04168-5.
3
Clinical and pathological analysis of indolent T-cell lymphoproliferative disease of the gastrointestinal tract.胃肠道惰性T细胞淋巴增殖性疾病的临床与病理分析
Front Immunol. 2025 May 21;16:1530149. doi: 10.3389/fimmu.2025.1530149. eCollection 2025.
4
Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring With Jakafi (Ruxolitinib) With Significant Clinical Improvements.使用Jakafi（芦可替尼）治疗伴有显著临床改善的胃肠道惰性T细胞淋巴瘤。
EJHaem. 2025 May 8;6(3):e70047. doi: 10.1002/jha2.70047. eCollection 2025 Jun.
5
Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification.成熟 B、T 和 NK 细胞、浆细胞和组织细胞/树突状细胞肿瘤：根据世界卫生组织和国际共识分类的分类。
J Hematol Oncol. 2024 Jul 8;17(1):51. doi: 10.1186/s13045-024-01570-5.
6
Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract Mimicking Crohn's Disease.酷似克罗恩病的胃肠道惰性T细胞淋巴增殖性疾病
Cureus. 2024 May 16;16(5):e60467. doi: 10.7759/cureus.60467. eCollection 2024 May.
7
Indolent T Cell Lymphoproliferation of the Gastrointestinal Tract: An Evolving Disease Entity.胃肠道惰性T细胞淋巴增殖性疾病：一种不断演变的疾病实体
Hematol Rep. 2024 Mar 22;16(2):179-184. doi: 10.3390/hematolrep16020018.
8
Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.结外成熟 T 细胞和 NK 细胞淋巴瘤和淋巴增殖性疾病的生物学和遗传学。
Haematologica. 2023 Dec 1;108(12):3261-3277. doi: 10.3324/haematol.2023.282718.
9
Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.寥寥无几：罕见结外成熟 T 细胞和 NK 细胞淋巴瘤的临床处理方法。
Haematologica. 2023 Dec 1;108(12):3244-3260. doi: 10.3324/haematol.2023.282717.
10
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.T 细胞淋巴瘤和淋巴组织增生性疾病分类的更新。
Curr Hematol Malig Rep. 2023 Dec;18(6):252-263. doi: 10.1007/s11899-023-00712-9. Epub 2023 Oct 23.
本文引用的文献
1
STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia.STAT3 突变及其与 T 细胞大颗粒淋巴细胞白血病的临床和组织病理学相关性。
Hum Pathol. 2018 Mar;73:74-81. doi: 10.1016/j.humpath.2017.12.014. Epub 2017 Dec 27.
2
Fusion of the genes ataxin 2 like, , and Janus kinase 2, , in cutaneous CD4 positive T-cell lymphoma.皮肤CD4阳性T细胞淋巴瘤中ataxin 2样基因与Janus激酶2基因的融合
Oncotarget. 2017 Oct 10;8(61):103775-103784. doi: 10.18632/oncotarget.21790. eCollection 2017 Nov 28.
3
Identification of novel recurrent - fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/-.在缺乏t(15;17)(q22;q12)/-的急性早幼粒细胞白血病中鉴定新的复发性融合基因
Blood. 2018 Feb 22;131(8):935-939. doi: 10.1182/blood-2017-09-807370. Epub 2017 Dec 13.
4
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.用于治疗炎症性和肿瘤性疾病的 Janus 激酶（JAK）抑制剂
Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.
5
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.芦可替尼在伴有PCM1-JAK2融合基因的髓系肿瘤中的疗效。
Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.
6
Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.淋巴瘤发生过程中JAK/STAT信号通路失调及其对新型靶向治疗开发的意义。
Blood Rev. 2015 Nov;29(6):405-15. doi: 10.1016/j.blre.2015.06.002. Epub 2015 Jun 11.
7
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.趋同突变和激酶融合导致间变性大细胞淋巴瘤中致癌性STAT3激活。
Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006.
8
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.源自γδ-T细胞或NK细胞的淋巴瘤中STAT5B和STAT3的激活突变。
Nat Commun. 2015 Jan 14;6:6025. doi: 10.1038/ncomms7025.
9
Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.胃肠道惰性 T 细胞淋巴组织增生性疾病。
Blood. 2013 Nov 21;122(22):3599-606. doi: 10.1182/blood-2013-07-512830. Epub 2013 Sep 5.
10
Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features.惰性小肠 CD4+ T 细胞淋巴瘤是一种具有独特生物学和临床特征的独特实体。
PLoS One. 2013 Jul 4;8(7):e68343. doi: 10.1371/journal.pone.0068343. Print 2013.
Zotero 插件